Revolutionizing pulpotomy-Bioceramic Bioactive MTA and Formocresol

Comparative evaluation of clinical and radiographic outcomes of Bioceramic Bioactive MTA and Formocresol as pulpotomy agents in primary molars- A randomized control trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/075425

Enrollment

Registered

2024-10-17

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K040- Pulpitis Health Condition 2: K040- Pulpitis

Interventions

Intervention1: Bioceramic Bioactive MTA: Bioceramic Bioactive MTA is an bioactive material that stimulated hydroxyapetite formation and promotes healing and can be used as an alternative medicament fo

Eligibility

Inclusion criteria

Inclusion criteria: • Primary mandibular teeth with carious lesion approximating pulp • No clinical or radiographic evidence of pulp degeneration • Restorable teeth • No physiological resorption of more than one third of the root

Exclusion criteria

Exclusion criteria: • History of spontaneous pain • Presence of systemic pathology • History of allergy to latex, local anesthesia, constituents of pulp dressing agents • Profuse bleeding after amputation of coronal pulp • Presence of pathologic mobility • Presence of gingival pathology

Design outcomes

Primary

Measure	Time frame
clinical outcomes:-pathology, mobility, gingival changes, percussion sensitivity, pain radiographic outcomes:-periodontal widening, abnormal trabeculations,radiolucency, abnormal root resorbtionTimepoint: 3 months, 6 months, 12 months	—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactDr KAAVYA I S

PMS COLLEGE OF DENTAL SCIENCE AND RESEARCH

DJMdeepak@gmail.com8086534000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026